US Cracks Down on Antidepressant Overuse With Bold New Reforms

Health Secretary Robert F. Kennedy Jr. has unveiled new measures to cut back on the widespread use of antidepressants. The plan targets selective serotonin reuptake inhibitors (SSRIs), a group of drugs including Zoloft, Lexapro, Paxil, and Prozac. Currently, around one in six American adults—16.6%—are prescribed these medications for depression and anxiety. The initiative shifts away from treating psychiatric drugs as the automatic first choice. Kennedy issued a 'Dear Colleague' letter urging providers to prioritise nonpharmacologic treatments and ensure patients fully understand their options. Shared decision-making and clearer informed consent will now play a larger role in treatment plans.

New clinical guidelines for safely reducing or stopping medications, known as deprescribing, will be developed by the Department of Health and Human Services. Meanwhile, the Substance Abuse and Mental Health Services Administration will release training modules to help clinicians guide patients through tapering. Many patients experience difficult withdrawal effects, such as 'brain zaps', restlessness, and flulike symptoms, when lowering doses or quitting SSRIs. To support these changes, the Centers for Medicare and Medicaid Services will introduce a reimbursement system. This will allow clinicians to bill for the time spent assisting patients in coming off medications. The goal is to reduce unnecessary long-term dependence while improving overall patient outcomes.

The reforms aim to give patients more control over their mental health treatment. By expanding access to non-drug therapies and providing clearer pathways off medication, the government hopes to address concerns about overprescription. The new guidelines and payment structures are set to take effect in the coming months.